Johnson & Johnson (JNJ) FCF Margin (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly FCF Margin came in at 6.09% in Q1 2026, down 935.0% year-on-year from 0.73% in Q1 2025, and down 72.67% quarter-over-quarter from 22.28% in Q4 2025.
Johnson & Johnson (JNJ) FCF Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed FCF Margin across 18 years of filings, most recently posting 6.09% for Q1 2026.
- FCF Margin for Q1 2026 came in at 6.09%, down 935.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 18.46% (down 435.0% YoY), and the FY2025 annual result was 20.91%, down 143.0% from the prior year.
- FCF Margin came in at 6.09% for Q1 2026 at Johnson & Johnson, down from 22.28% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 33.39% in Q3 2025 to a low of 6.09% in Q1 2026.
- The 5-year median for FCF Margin is 17.0% (2022), against an average of 19.29%.
- Across the five-year window, FCF Margin jumped 2058 bps in 2023 and sank 935 bps in 2026, its largest moves.
- Johnson & Johnson's FCF Margin stood at 17.0% in 2022, then surged by 73 bps to 29.32% in 2023, then fell by 19 bps to 23.85% in 2024, then slipped by 7 bps to 22.28% in 2025, then slumped by 73 bps to 6.09% in 2026.
- The last three FCF Margin figures came in at 6.09% (Q1 2026), 22.28% (Q4 2025), and 33.39% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 20.59% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 15.19% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 6.09% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 23.76% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 17.97% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 17.14% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 34.87% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 93.16% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 6.59% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 6.09% |
| Dec 28, 2025 | 22.28% |
| Sep 28, 2025 | 33.39% |
| Jun 29, 2025 | 11.94% |
| Mar 30, 2025 | 15.43% |
| Dec 29, 2024 | 23.85% |
| Sep 29, 2024 | 30.99% |
| Jun 30, 2024 | 20.75% |
| Mar 31, 2024 | 13.33% |
| Dec 31, 2023 | 29.32% |
| Oct 1, 2023 | 30.55% |
| Jul 2, 2023 | 14.21% |
| Apr 2, 2023 | 11.46% |
| Jan 1, 2023 | 8.75% |
| Apr 3, 2022 | 17.00% |
| Oct 3, 2021 | 32.32% |
| Jul 4, 2021 | 19.31% |
| Apr 4, 2021 | 15.22% |
| Jan 3, 2021 | 31.23% |
| Sep 27, 2020 | 36.27% |